目录号：MS-855
小鼠单克隆抗体（克隆号 CAS-14）

应用
* 对常规的经福尔马林处理的和石蜡包埋的组织进行免疫组化染色
* Western Blotting
* 免疫沉淀

生物学背景
p130 Cas是一种130kDa的docking蛋白，含于不同的生物学步骤中：
* Cell Adhesion
* Cell Proliferation
* Cell Migration
* Possibly Oncogenic Transformation

激素治疗乳腺癌的Tamoxifen-A
Tamoxifen（三苯氧胺），是一种选择性雌激素受体调节器（SERM）。它是目前应用最广泛的内分泌治疗法，适用于各个阶段的激素引起的乳腺癌的治疗。
尽管不能提高由雌激素受体(-)和黄体酮受体(-)引起的肿瘤的存活率，但Tamoxifen可以提高在乳癌ER(+)早期阶段的病人的无复发和完全存活率。

p130 Cas在乳腺癌中的Prognostic Value
在处于乳腺癌ER(+)早期阶段的病人体内，高p130 Cas水平与下列因素有关：
* 低无复发和完全存活率
* 疾病迅速复发
* 抗Tamoxifen的高风险性

相关产品价目表：

目录号	产品说明	规格	价格(元)
MS-855P0	p130 Cas Ab-1(Purified Ab with BSA and Azide)	0.1ml	700
MS-855P1	p130 Cas Ab-1(Purified Ab with BSA and Azide)	0.5ml	2926
MS-855P	p130 Cas Ab-1(Purified Ab with BSA and Azide)	1ml	4466
MS-855P1ABX	p130 Cas Ab-1(Purified Ab without BSA and Azide)	100μl	3346
MS-855PABX	p130 Cas Ab-1(Purified Ab without BSA and Azide)	200μl	4886
MS-855R7	p130 Cas Ab-1(7.0ml Ready for Histology)	7ml	3206
MS-855PCL	p130 Cas Ab-1(Positive Control for Histology)	100μl	980
MS-855PCS	p130 Cas Ab-1(Positive Control for Western Blot)	5slides	840
MS-855B0	p130 Cas Ab-1(Biotin-Labeled Ab with BSA and Azide)	0.1ml	1400
MS-855B	p130 Cas Ab-1(Biotin-Labeled Ab with BSA and Azide)	0.5ml	5726
MS-855B1	p130 Cas Ab-1(Biotin-Labeled Ab with BSA and Azide)	1ml	3766
MS-855F0	p130 Cas Ab-1(FITC-Labeled Ab with BSA and Azide)	0.1ml	1400
MS-855F	p130 Cas Ab-1(FITC-Labeled Ab with BSA and Azide)	0.5ml	5726
MS-855F1	p130 Cas Ab-1(FITC-Labeled Ab with BSA and Azide)	1ml	3766
MS-855PE0	p130 Cas Ab-1(PE-Labeled Ab with BSA and Azide)	0.1ml	1400
MS-855PE	p130 Cas Ab-1(PE-Labeled Ab with BSA and Azide)	0.5ml	5726
MS-855PE1	p130 Cas Ab-1(PE-Labeled Ab with BSA and Azide)	1ml	3766

参考文献：
1. O'Regan RM, Gradishar WJ: Selective Estrogen-Receptor Modulators in 2001. Oncology 2001 Sep; 15(9): 1178-85, 1189-90, 1190-4
2. Muss HB: Role of Adjuvant Endocrine Therapy in Early-Stage Breast Cancer. Semin Oncol 2001 Aug;28(4): 313-21
3. Brinkman A, van der Flier S, Kok EM, Dorssers LC: BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 2000 Jan 19; 92(2): 112-20
4. van der Flier S, Brinkman A, Look MP, Kok EM, Meijer-van Gelder ME, Klijn JG, Dorssers LC, Foekens JA: Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 2000 Jan 19; 92(2): 120-7